Despite CAR-T cell therapies’ strong track record of efficacy in hematological cancers, success has been largely elusive in solid tumors. But updated data from BioNTech SE’s Phase I/II study of BNT211 indicate that the German biotech company may have found a way to bring CAR-Ts into the solid tumor realm.
ESMO 2023: Could BioNTech’s BNT211 Break Out Of The CAR-T Solid Tumor Cage?
The German biotech presented updated data at ESMO showing strong efficacy in ovarian cancer and other solid tumors, albeit with a higher degree of adverse events, particularly cytokine release syndrome.
